Results 71 to 80 of about 535,121 (211)

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Comparisons of in vitro Fick’s first law, lipolysis, and in vivo rat models for oral absorption on BCS II drugs in SNEDDS

International Journal of Nanomedicine, 2019
Jingyi Ye,1,* Huiyi Wu,1,* Chuanli Huang,1 Wanting Lin,2 Caifeng Zhang,1 Bei Huang,2 Banyi Lu,2 Hongyu Xu,2 Xiaoling Li,3 Xiaoying Long1,41Department of Pharmaceutics, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, People&
Ye J, Wu H, Huang C, Lin W, Zhang C, Huang B, Lu B, Xu H, Li X, Long X   +9 more
doaj  

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

In Vitro Evaluation of Poly(D,L-lactide-co-glycolide) In Situ Gels and Pharmacokinetics Following Subcutaneous Injection in Rats for Model Drugs

Pharmaceutics
Background/Objectives. This research supports the development of long-acting injectables (LAIs) via in situ gel (ISG) technology by illustrating the influence of drug properties and formulation variables on in vitro drug release (Part 1), and providing ...
Sandy Van Hemelryck, Charlotte Vercammen, Eline Seldeslachts, Koen Wuyts, Ils Pijpers, René Holm, Erik Mannaert, Peter Langguth   +7 more
doaj   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

In Vitro – In Vivo Correlation of Pentoxifylline: A Comprehensive Kinetic Analysis

Studia Universitatis Babes-Bolyai Chemia
This study presents an analysis of In Vitro-In Vivo Correlation (IVIVC) for pentoxifylline modified-release tablets, with a focus on deriving robust predictive models.
Maria CODREANU, Diana IACOB, Maria Ioana ONOFREI, Ana-Maria VLASE, Dana Maria MUNTEAN, Laurian VLASE   +5 more
doaj   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

In vitro release and in vitro–in vivo correlation for silybin meglumine incorporated into hollow-type mesoporous silica nanoparticles

International Journal of Nanomedicine, 2012
Xia Cao*, Wen-Wen Deng*, Min Fu*, Liang Wang, Shan-Shan Tong, Ya-Wei Wei, Ying Xu, Wei-Yan Su, Xi-Ming Xu, Jiang-Nan YuDepartment of Pharmaceutics, School of Pharmacy, and Center for Nano Drug/Gene Delivery and Tissue Engineering, Jiangsu University ...
Cao X, Deng WW, Fu M, Wang L, Tong SS, Wei YW, Xu Y, Su WY, Xu XM, Yu JN   +8 more
doaj  

Nanoparticles for drug delivery: Insight into in vitro and in vivo drug release from nanomedicines

Nano TransMed
Nanotechnology enables the achievement of the desired outcomes of nano-formulations, and the mode of drug delivery from the nanoparticles can significantly impact the efficacy of the embedded drug. This article reviews the various types of nanoparticles,
Ugochi E. Ewii, Anthony A. Attama, Emmanuel O. Olorunsola, Adaeze Linda Onugwu, Fortune Uchechukwu Nwakpa, Chioma Anyiam, Chinonye Chijioke, Toochukwu Ogbulie   +7 more
doaj   +1 more source